loading page

Evaluation of nine serological rapid tests for detection of SARS-CoV-2 in Colombia.
  • +12
  • Marcela Mercado,
  • Jeadran Malagón Rojas,
  • Gabriela Delgado,
  • Vivian Rubio,
  • Lida Muñoz Galindo,
  • Eliana L. Parra ,
  • Paula Gaviria,
  • Gabriela Zabaleta,
  • Zonia Alarcon,
  • Adriana Arévalo,
  • Kelly Estrada,
  • Gloria Puerto,
  • María Herrera Sepúlveda,
  • Helena Rodríguez,
  • Martha Ospina Ramírez
Marcela Mercado
Instituto Nacional de Salud
Author Profile
Jeadran Malagón Rojas
Universidad El Bosque
Author Profile
Gabriela Delgado
Universidad Nacional de Colombia
Author Profile
Vivian Rubio
Instituto Nacional de Salud
Author Profile
Lida Muñoz Galindo
Instituto Nacional de Salud
Author Profile
Eliana L. Parra
Instituto Nacional de Salud
Author Profile
Paula Gaviria
Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud-IDCBIS.
Author Profile
Gabriela Zabaleta
Instituto Nacional de Salud
Author Profile
Zonia Alarcon
Insituto Nacional de Salud
Author Profile
Adriana Arévalo
Instituto Nacional de Salud
Author Profile
Kelly Estrada
Instituto de Evaluación Tecnológica en Salud
Author Profile
Gloria Puerto
Instituto Nacional de Salud
Author Profile
María Herrera Sepúlveda
Instituto Nacional de Salud
Author Profile
Helena Rodríguez
Instituto Nacional de Salud
Author Profile
Martha Ospina Ramírez
Instituto Nacional de Salud
Author Profile

Abstract

As an emergent virus, serological testing for SARS-Cov-2 is crucial. Even though the detection of the virus has been based by using RT-PCR, the serological tests for antibody detection are also need. This study evaluated nine SARS-CoV-2 IgM/IgG commercial rapid tests. Methods: a cross-sectional study of diagnosis test was designed to compare the performance of the evaluated immunochromatographic tests for the diagnosis of SARS-CoV-2. It was used a total of 293 samples including negatives, asymptomatic and symptomatic serum samples. Results: the sensibility of the evaluated tests were low and moderate in the groups of asymptomatic serum samples and in the group of serums coming from patients with less than 11 days since the symptoms onset. Conclusion: The usefulness of these tests is restricted to symptomatic patients and their sensitivity is greater than 85% after 11 days from the appearance of symptoms.